Literature DB >> 11056010

Estrogen-induced resistance to osteoblast apoptosis is associated with increased hsp27 expression.

L F Cooper1, J C Tiffee, J P Griffin, H Hamano, Z Guo.   

Abstract

Estrogen has been shown to protect osteoblastic cells from apoptosis. Similarly, estrogen treatment preceding heat shock elevates heat shock protein 27 (hsp27) expression and increases thermoresistance in the murine estrogen receptor-transformed SMER14 osteoblastic cell line. Forced expression of hsp27 expression in other cell lines limits apoptosis. The purpose of this study was to examine the effects of estrogen on staurosporine-induced apoptosis in the context of hsp27 expression. Cell viability was measured by the MTT assay. Early apoptotic events were examined by fluorescent microscopy by using FITC-conjugated Annexin V staining. TUNEL labeling was used to compare the number of apoptotic nuclei following staurosporine treatment of estrogen pretreated or untreated cells. Estrogen treatment increased SMER14 cell viability, but not ROS17/2.8 cell viability, in the presence of staurosporine. Estrogen treatment also reduced annexin V staining and DNA fragmentation. Similar treatment increased SMER14 cell hsp27 levels. The concurrent reduction in induced apoptosis suggests a possible estrogenic mechanism for increasing and/or maintaining the number of viable osteoblasts in bone. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11056010     DOI: 10.1002/1097-4652(200012)185:3<401::AID-JCP10>3.0.CO;2-C

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane.

Authors:  Mahnaz Razandi; Gordon Alton; Ali Pedram; Sanjiv Ghonshani; Paul Webb; Ellis R Levin
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

2.  Long-term culture in dexamethasone unmasks an abnormal phenotype in osteoblasts isolated from osteoporotic subjects.

Authors:  L G Rao; T M Murray; J N Wylie; R J McBroom; M Kung Sutherland
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

3.  Response of a preosteoblastic cell line to cyclic tensile stress conditioning and growth factors for bone tissue engineering.

Authors:  Eunna Chung; Marissa Nichole Rylander
Journal:  Tissue Eng Part A       Date:  2011-11-08       Impact factor: 3.845

4.  Response of preosteoblasts to thermal stress conditioning and osteoinductive growth factors.

Authors:  Eunna Chung; Marissa Nichole Rylander
Journal:  Cell Stress Chaperones       Date:  2011-11-25       Impact factor: 3.667

5.  Glycitein decreases the generation of murine osteoclasts and increases apoptosis.

Authors:  Maria Winzer; Martina Rauner; Peter Pietschmann
Journal:  Wien Med Wochenschr       Date:  2010-08-16

6.  Participation of HSP27 in the antiapoptotic action of 17beta-estradiol in skeletal muscle cells.

Authors:  Andrea Vasconsuelo; Lorena Milanesi; Ricardo Boland
Journal:  Cell Stress Chaperones       Date:  2009-07-21       Impact factor: 3.667

7.  Heat shock protein 27 overexpression mitigates cytokine-induced islet apoptosis and streptozotocin-induced diabetes.

Authors:  Tiane Dai; Mina Patel-Chamberlin; Rama Natarajan; Ivan Todorov; Jun Ma; Janine LaPage; Lynetta Phillips; Cynthia C Nast; Diana Becerra; Peter Chuang; Lili Tong; Jacqueline de Belleroche; Dominic J Wells; Ying Wang; Sharon G Adler
Journal:  Endocrinology       Date:  2009-03-26       Impact factor: 4.736

Review 8.  Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?

Authors:  Richard A Steinman; Adam M Brufsky; Steffi Oesterreich
Journal:  Breast Cancer Res       Date:  2012-09-21       Impact factor: 6.466

Review 9.  ERα, A Key Target for Cancer Therapy: A Review.

Authors:  Yanfang Liu; Hong Ma; Jing Yao
Journal:  Onco Targets Ther       Date:  2020-03-11       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.